Virtu Financial’s Allogene Therapeutics ALLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-97,591
Closed -$203K – 1541
2026
Q2
$203K Sell
97,591
-1,094
-1% -$2.4K 0.01% 925
2026
Q1
$241K Buy
98,685
+56,334
+133% +$113K 0.01% 930
2025
Q4
$58K Buy
42,351
+15,178
+56% +$20K ﹤0.01% 1282
2025
Q3
$34K Buy
27,173
+2,315
+9% +$2.76K ﹤0.01% 1198
2025
Q2
$28K Buy
+24,858
New +$33K ﹤0.01% 1215
2023
Q2
– Sell
-13,561
Closed -$67K – 1477
2023
Q1
$67K Buy
+13,561
New +$87K 0.01% 1052
2022
Q4
– Sell
-24,128
Closed -$261K – 1549
2022
Q3
$261K Buy
+24,128
New +$328K 0.02% 723
2022
Q1
– Sell
-35,652
Closed -$532K – 1461
2021
Q4
$532K Buy
+35,652
New +$629K 0.05% 345
2019
Q4
– Sell
-9,027
Closed -$246K – 1409
2019
Q3
$246K Buy
+9,027
New +$257K 0.02% 857

Other funds holding ALLO

Virtu Financial's ALLO Position: Q3 2026 in Review

Virtu Financial sold out of Allogene Therapeutics (ALLO) in Q3 2026, closing a stake of 97,591 shares — an estimated $203K sold.

Virtu Financial first reported a position in ALLO in Q3 2019 and held it in 9 quarters. The position peaked at $532K in Q4 2021. 198 funds tracked by Wall St. Rank hold ALLO as of Q3 2026.

  • Virtu Financial reported no remaining Allogene Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Virtu Financial sold 97,591 Allogene Therapeutics shares in Q3 2026, an estimated $203K.
  • Virtu Financial first reported a position in Allogene Therapeutics in Q3 2019 and held it in 9 quarters.
  • Virtu Financial's Allogene Therapeutics position peaked at $532K in Q4 2021.
  • 198 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2026.

Based on Virtu Financial's 13F filing for Q3 2026, filed 17 Nov 2026.